Clinical Scorecard: Toxoplasmosis in the Immunocompromised Eye

At a Glance

Key Highlights

• The review included clinical data from 276 immunocompromised patients and 345 affected eyes; HIV was the most common cause of immunocompromise.
• Among eyes with available data, 76.4% had presenting visual acuity of 6/15 or worse, and 55.7% had acuity of 6/60 or worse.
• Multifocal lesions were reported in 41.3% of eyes, and macular or peripapillary involvement in 77.4% of eyes with location data.
• The review authors report that the initial diagnosis was missed in more than half of published cases with sufficient clinical information.
• The review considers any active toxoplasmic retinal lesion an indication for systemic antiparasitic therapy.

Guideline-Based Recommendations

Diagnosis

• The review describes ocular toxoplasmosis presentations without the classic lesion adjacent to a pigmented retinochoroidal scar.
• The review reports that lesions may be multifocal, large, diffuse, or resemble acute retinal necrosis or cytomegalovirus retinitis.
• The review authors highlight molecular analysis of ocular fluid as particularly important when presentation is atypical.

Management

• The review considers any active toxoplasmic retinal lesion in an immunocompromised patient an indication for systemic antiparasitic therapy.
• Reported regimens varied; pyrimethamine plus sulfadiazine was the most commonly reported combination.

Monitoring & Follow-up

• The source does not provide a specific monitoring recommendation.

Risks

• The review notes that retinal lesions may continue enlarging without treatment in immunocompromised patients.
• The review reports frequent atypical presentations and diagnostic uncertainty; it describes poor visual outcomes in the reviewed cases.

Patient & Prescribing Data

The review covered immunocompromised patients, including people with HIV, transplant recipients, patients taking immunomodulatory therapies, people with malignancies, and people with primary immunodeficiencies.

Systemic antiparasitic regimens varied across reports; pyrimethamine plus sulfadiazine was the most commonly reported combination.

Clinical Best Practices

• The review describes atypical retinal lesions in immunocompromised patients as a diagnostic challenge.
• The review authors highlight molecular analysis of ocular fluid when presentation is atypical.
• The review considers systemic antiparasitic therapy indicated for active toxoplasmic retinal lesions in immunocompromised patients.
• The authors suggest routine immune-status stratification in clinical studies to clarify how forms of immunodeficiency affect presentation, diagnosis, and treatment.

Related Resources & Content

• Kreps et al., review of ocular toxoplasmosis in patients with systemic immunocompromise, Progress in Retinal and Eye Research